Breaking News
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Oculis announced completion of randomization in the PREDICT-1 registrational trial for Licaminlimab, a precision medicine treatment for TNFR1-mediated dry eye disease. The trial enrolled 176 patients, with two-thirds carrying the specific TNFR1 genetic variant associated with improved clinical response. Topline results are expected around year-end 2026. If approved, Licaminlimab could become the first precision medicine treatment for an estimated 1.5 million Americans with moderate to severe TNFR1-mediated dry eye disease.
Latest News
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Oculis announced completion of randomization in the PREDICT-1 registrational trial for Licaminlimab, a precision medicine treatment for TNFR1-mediated dry eye disease. The trial enrolled 176 patients, with two-thirds carrying the specific TNFR1 genetic variant associated with improved clinical response. Topline results are expected around year-end 2026. If approved, Licaminlimab could become the first precision medicine treatment for an estimated 1.5 million Americans with moderate to severe TNFR1-mediated dry eye disease.
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix Pharmaceuticals has partnered with Ekalia (a joint venture between IBA and Framatome) to establish dedicated U.S. production of astatine-211, a scarce alpha-emitting isotope for targeted alpha therapy. The collaboration will install IBA's alpha-beam cyclotron at Telix's RLS Radiopharmacies site near Philadelphia, securing long-term isotope access for Telix's pipeline including TLX102-Tx for glioblastoma, while also supporting third-party programs.
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate Astatine-211 production in the United States. The partnership will establish the first US production unit at RLS Trevose in Pennsylvania, with potential for further expansion. Telix will secure access to a portion of the production capacity to advance its alpha therapy pipeline.
Ekalia franchit une étape importante dans le déploiement de l’astate-211 aux États-Unis grâce à un accord de collaboration avec Telix
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate astatine-211 (At-211) production in the United States. The partnership will leverage Telix's radiopharmaceutical network (RLS Radiopharmacies) to establish the first US production facility in Trevose, Pennsylvania, addressing the current shortage of this promising alpha-emitting radioisotope for cancer therapies.
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Roche announced it will present pivotal Phase III data at ESMO 2026 demonstrating divarasib's superiority over first-generation KRAS G12C inhibitors in lung cancer, giredestrant's improved efficacy without compromising quality of life in breast cancer, and Tam-Peli's robust efficacy in nasopharyngeal carcinoma. These presentations highlight advances across Roche's oncology pipeline with potential to establish new standards of care across multiple cancer types.
Red Cat Announces Proposed Voluntary Public Purchase Offer for Steyr Motors
Red Cat Holdings announced a proposed voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG, an Austrian leader in customized engines for defense applications, for EUR 39.00 per share in cash. The acquisition is supported by Steyr Motors' anchor shareholder B&C Group and aims to strengthen Red Cat's uncrewed surface vessel strategy while maintaining Steyr Motors' Austrian headquarters and operations. The offer represents a 28.9% premium to the October 16, 2026 closing price, with an acceptance period expected to end on December 18, 2026.
Mowi ASA (OSE:MOWI): Q3 2026 Trading update
Mowi achieved record quarterly harvest volumes of 186 thousand tonnes in Q3 2026, up from 166 thousand tonnes in Q3 2025. Operational EBIT reached a seasonally record-high of EUR 275 million, with blending farming costs declining by EUR 0.31/kg to EUR 5.11/kg. The company reported net interest-bearing debt of approximately EUR 2,886 million.
Warren Buffett Warned About Stock Valuations. So Why Is Berkshire Still Buying Stocks?
Despite warning in May that stock valuations were too high, Warren Buffett's Berkshire Hathaway has reversed course and become more aggressive in buying stocks and repurchasing its own shares since Q2. The company has invested in Alphabet and Bending Spoons while the S&P 500 has risen 7% since Buffett's warning, suggesting that actions speak louder than words when it comes to investment strategy.
Synaptics' Key Insider Rahul Patel Sells Shares
Synaptics CEO Rahul Patel sold 2,276 shares worth $213,557 in an SEC Form 4 filing. The sale was executed under a pre-arranged 10b5-1 trading plan, which means investors should not interpret it as a signal of insider concern. Other executives also sold shares under similar plans. Synaptics stock has significantly outperformed the Nasdaq this year, gaining 58.3% through October 16.
Intelligent Scopes Unveils the ISC 100: The Solution Enabling Urology AI to Work Beside Any Cystoscopy Tower — No Replacement, No Rewiring, No Cloud
Intelligent Scopes Corp unveiled the ISC 100, a compact edge computing appliance that enables AI-powered urology software to operate alongside existing cystoscopy equipment without requiring replacement or rewiring. Built on NVIDIA Jetson Orin, the device runs locally without cloud connectivity and has received regulatory clearance in Brazil and Singapore for its CystoSmart software, with FDA and other approvals pending.